Linked Life Data

19389495

Source:http://linkedlifedata.com/resource/pubmed/id/19389495

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-4-24
pubmed:abstractText
The treatment of newly diagnosed myeloma has evolved rapidly. The choice of initial therapy depends on eligibility for stem cell transplantation, as well as baseline risk factors. Eligibility for transplantation is important since the choice of initial therapy is primarily melphalan-based in patients who are not candidates for transplant, while melphalan-containing regimens are avoided as induction therapy in transplant candidates. An assessment of risk based on independent prognostic markers is important mainly for prognosis but may have some value in choice of initial therapy. For example, bortezomib-based regimens may have particular value in patients with certain high-risk features. This review discusses the current status of front-line therapy in younger patients with myeloma who are candidates for stem cell transplantation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0037-1963
pubmed:author
pubmed:issnType
Print
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
118-26
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Front-line treatment in younger patients with multiple myeloma.
pubmed:affiliation
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural